171 related articles for article (PubMed ID: 25347821)
1. Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model.
Cohen OR; Steele JA; Zhang Q; Schmidt DJ; Wang Y; Hamel PE; Beamer G; Xu B; Tzipori S
PLoS One; 2014; 9(10):e111075. PubMed ID: 25347821
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
[TBL] [Abstract][Full Text] [Related]
3. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).
Leav BA; Blair B; Leney M; Knauber M; Reilly C; Lowy I; Gerding DN; Kelly CP; Katchar K; Baxter R; Ambrosino D; Molrine D
Vaccine; 2010 Jan; 28(4):965-9. PubMed ID: 19941990
[TBL] [Abstract][Full Text] [Related]
4. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.
Babcock GJ; Broering TJ; Hernandez HJ; Mandell RB; Donahue K; Boatright N; Stack AM; Lowy I; Graziano R; Molrine D; Ambrosino DM; Thomas WD
Infect Immun; 2006 Nov; 74(11):6339-47. PubMed ID: 16966409
[TBL] [Abstract][Full Text] [Related]
5. The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.
Steele J; Parry N; Tzipori S
Gut Microbes; 2014; 5(1):53-7. PubMed ID: 24394234
[TBL] [Abstract][Full Text] [Related]
6. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.
Andersen KK; Strokappe NM; Hultberg A; Truusalu K; Smidt I; Mikelsaar RH; Mikelsaar M; Verrips T; Hammarström L; Marcotte H
Infect Immun; 2016 Feb; 84(2):395-406. PubMed ID: 26573738
[TBL] [Abstract][Full Text] [Related]
8. A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.
Anosova NG; Cole LE; Li L; Zhang J; Brown AM; Mundle S; Zhang J; Ray S; Ma F; Garrone P; Bertraminelli N; Kleanthous H; Anderson SF
Clin Vaccine Immunol; 2015 Jul; 22(7):711-25. PubMed ID: 25924765
[TBL] [Abstract][Full Text] [Related]
9. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY
BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596
[TBL] [Abstract][Full Text] [Related]
10. Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors.
von Eichel-Streiber A; Paik W; Knight K; Gisch K; Nadjafi K; Decker C; Bosnjak O; Cheknis A; Johnson S; von Eichel-Streiber C
Anaerobe; 2016 Oct; 41():91-103. PubMed ID: 27427464
[TBL] [Abstract][Full Text] [Related]
11. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.
Castagliuolo I; Riegler MF; Valenick L; LaMont JT; Pothoulakis C
Infect Immun; 1999 Jan; 67(1):302-7. PubMed ID: 9864230
[TBL] [Abstract][Full Text] [Related]
12. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.
Steele J; Mukherjee J; Parry N; Tzipori S
J Infect Dis; 2013 Jan; 207(2):323-30. PubMed ID: 23125448
[TBL] [Abstract][Full Text] [Related]
13. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.
Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL
Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481
[TBL] [Abstract][Full Text] [Related]
14. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
[TBL] [Abstract][Full Text] [Related]
15. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.
Zhang Z; Chen X; Hernandez LD; Lipari P; Flattery A; Chen SC; Kramer S; Polishook JD; Racine F; Cape H; Kelly CP; Therien AG
Infect Immun; 2015 Jan; 83(1):405-16. PubMed ID: 25385797
[TBL] [Abstract][Full Text] [Related]
16. The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice.
McDermott AJ; Higdon KE; Muraglia R; Erb-Downward JR; Falkowski NR; McDonald RA; Young VB; Huffnagle GB
Immunology; 2015 Apr; 144(4):704-16. PubMed ID: 25399934
[TBL] [Abstract][Full Text] [Related]
17. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.
Koon HW; Shih DQ; Hing TC; Yoo JH; Ho S; Chen X; Kelly CP; Targan SR; Pothoulakis C
Antimicrob Agents Chemother; 2013 Jul; 57(7):3214-23. PubMed ID: 23629713
[TBL] [Abstract][Full Text] [Related]
18. Treatment with monoclonal antibodies against Clostridium difficile toxins.
Lowy I; Molrine DC; Leav BA; Blair BM; Baxter R; Gerding DN; Nichol G; Thomas WD; Leney M; Sloan S; Hay CA; Ambrosino DM
N Engl J Med; 2010 Jan; 362(3):197-205. PubMed ID: 20089970
[TBL] [Abstract][Full Text] [Related]
19. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.
Guo S; Yan W; McDonough SP; Lin N; Wu KJ; He H; Xiang H; Yang M; Moreira MA; Chang YF
Vaccine; 2015 Mar; 33(13):1586-95. PubMed ID: 25698490
[TBL] [Abstract][Full Text] [Related]
20. A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection.
Schmidt DJ; Beamer G; Tremblay JM; Steele JA; Kim HB; Wang Y; Debatis M; Sun X; Kashentseva EA; Dmitriev IP; Curiel DT; Shoemaker CB; Tzipori S
Clin Vaccine Immunol; 2016 Sep; 23(9):774-84. PubMed ID: 27413067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
